Nothing said here yet.
to join the conversation.
| Lippis Daniel J.CVP, TAVR | Sell | 619 | $53.0K | Thu, Oct 8 |
| Lippis Daniel J.CVP, TAVR | Sell | 619 | $54.2K | Fri, Sep 11 |
| Dahl Andrew M.SVP, Corporate Controller | Sell | 544 | $49.5K | Mon, Aug 31 |
| Bruls AnnetteCVP, EMEACLA | Sell | 2,644 | $237.9K | Fri, Aug 28 |
| Chopra DaveenCVP, TMTT, Surgical & IHFM | Sell | 30,646 | $2.8M | Wed, Aug 26 |
| Markowitz WayneCVP, JAPAC | Sell | 1,240 | $113.4K | Wed, Aug 26 |
| Chopra DaveenCVP, TMTT, Surgical & IHFM | Sell | 1,154 | $105.9K | Wed, Aug 26 |
| Alan Armstrong | Buy | $8.0K | Fri, Mar 27 | Tue, Jul 21 |
EW heads into Q3 with TAVR momentum, expanding mitral and tricuspid therapies and surgical heart growth. Can it beat earnings estimates?
Beyond analysts' top-and-bottom-line estimates for Edwards Lifesciences (EW), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2026.
Edwards brings a decade of experience in technology policy, competition, and AI infrastructure to help early-stage founders navigate critical decisions as they build and scale. NEW YORK, Oct.
Edwards Lifesciences reported past FDA approvals for its PASCAL Precision system for tricuspid valve repair and PASCAL Ace with Capture Clarity for degenerative mitral TEER, giving the business a broader U.S. transcatheter repair toolkit for patients who are…
Edwards’ approval should “strengthen the company’s position in the large and underpenetrated transcatheter tricuspid market,” analysts said.
Edwards Lifesciences' TMTT and TAVR growth, strong clinical evidence and solid balance sheet support expansion, but tariffs and currency headwinds threaten margins.
The PASCAL Precision device is indicated to treat individuals with symptomatic severe tricuspid regurgitation.
Former BBC presenter says programme starring Martin Clunes gave a misleading and unfair account of his downfall Britain’s media regulator is investigating a complaint from the former BBC news presenter Huw Edwards about a Channel 5 drama depicting his…
The U.S. Food and Drug Administration (FDA) issued a high-risk early alert after Edwards Lifesciences Corp. (NYSE:EW) recalled specific lots of its Commander M delivery systems due to reports of balloons bursting during procedures, resulting in one death and…
An issue with the delivery component of Edwards’ SAPIEN M3 TMVR system has been associated with one patient death and one serious injury as of 5 October.